Vasamed, Inc. (VSMD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vasamed, Inc. (VSMD) with AI Score 59/100 (Hold). Vasamed, Inc. focuses on designing, manufacturing, and distributing products for hemodynamic health assessment. Their SensiLase PAD-IQ system and related software serve clinicians and patients in the United States. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Vasamed, Inc. (VSMD) Healthcare & Pipeline Overview
Vasamed Incorporated, established in 1988, specializes in hemodynamic health assessment solutions, including the SensiLase PAD-IQ system. Serving clinicians and patients in the United States, the company provides diagnostic tools and software for managing peripheral artery disease and wound care, operating within the medical instruments and supplies sector.
Investment Thesis
Vasamed, Inc. operates in the niche market of hemodynamic health assessment, primarily through its SensiLase PAD-IQ system. While the company's solutions cater to a specific need in vascular health management, the negative profit margin of -352.6% and gross margin of -5.0% raise concerns about its financial sustainability. Growth catalysts include potential expansion of the PAD-IQ system's applications and increased adoption of PAD-IQ Studycast for remote diagnostics. However, the company's reliance on a limited product line and the competitive landscape of medical instruments and supplies pose risks. Investors should closely monitor Vasamed's ability to improve its financial performance and capitalize on growth opportunities within the hemodynamic health market.
Based on FMP financials and quantitative analysis
Key Highlights
- Vasamed Incorporated specializes in hemodynamic health assessment products and services.
- The company's flagship product is the SensiLase PAD-IQ system, used for diagnosing peripheral artery disease (PAD).
- Vasamed offers PAD-IQ Studycast, a service for rapid transmission of diagnostic tests to vascular specialists.
- The company's profit margin is -352.6%, indicating significant losses.
- Vasamed operates in the medical instruments and supplies industry, serving clinicians and patients in the United States.
Competitors & Peers
Strengths
- Specialized product portfolio focused on hemodynamic health assessment.
- Proprietary SensiLase PAD-IQ system for accurate measurements.
- PAD-IQ Studycast service for remote diagnostics.
- Established relationships with clinicians and healthcare providers.
Weaknesses
- Negative profit margin of -352.6% indicates financial instability.
- Gross margin of -5.0% suggests challenges in cost management.
- Limited product line focused primarily on PAD diagnosis.
- Reliance on the U.S. market.
Catalysts
- Potential expansion of PAD-IQ system applications to other vascular conditions (timeline: 2-3 years).
- Increased adoption of PAD-IQ Studycast for telemedicine (timeline: 1-2 years).
- Strategic partnerships with healthcare providers.
- Development of new wound care solutions (timeline: 3-5 years).
- Geographic expansion beyond the United States (timeline: 4-6 years).
Risks
- Negative profit margin of -352.6% indicates financial instability.
- Gross margin of -5.0% suggests challenges in cost management.
- Competition from larger medical device companies.
- Regulatory changes impacting product development and market access.
- Economic downturn affecting healthcare spending.
Growth Opportunities
- Expansion of PAD-IQ System Applications: Vasamed can explore expanding the applications of its PAD-IQ system beyond PAD diagnosis to include other vascular conditions. This could involve developing new software modules or hardware attachments that enable the system to assess different hemodynamic parameters or target specific patient populations. The market for vascular diagnostic tools is estimated to reach $10 billion by 2028, providing a significant opportunity for Vasamed to increase its market share by diversifying the applications of its flagship product. Timeline: 2-3 years.
- Increased Adoption of PAD-IQ Studycast: Vasamed can focus on increasing the adoption of its PAD-IQ Studycast service, which facilitates remote transmission of diagnostic tests to vascular specialists. This service addresses the growing demand for telemedicine solutions and can improve access to specialized care, particularly in rural or underserved areas. The telemedicine market is projected to reach $400 billion by 2027, presenting a substantial opportunity for Vasamed to expand its Studycast service and generate recurring revenue. Timeline: 1-2 years.
- Strategic Partnerships with Healthcare Providers: Vasamed can pursue strategic partnerships with hospitals, clinics, and vascular centers to integrate its products and services into their existing workflows. This could involve offering bundled solutions that combine the PAD-IQ system with training, support, and data analytics services. By partnering with established healthcare providers, Vasamed can gain access to a broader customer base and increase its market penetration. Timeline: Ongoing.
- Development of New Wound Care Solutions: Vasamed can leverage its expertise in hemodynamic assessment to develop new wound care solutions that complement its existing Wound Imaging & SmartDraw system. This could involve incorporating advanced imaging technologies or developing novel wound dressings that promote healing and reduce the risk of infection. The wound care market is expected to reach $22 billion by 2029, providing a significant opportunity for Vasamed to expand its product portfolio and address unmet needs in wound management. Timeline: 3-5 years.
- Geographic Expansion Beyond the United States: Vasamed can explore expanding its operations beyond the United States to target international markets with a high prevalence of vascular disease. This could involve adapting its products and services to meet the specific needs of different healthcare systems and regulatory environments. By expanding its geographic reach, Vasamed can diversify its revenue streams and reduce its reliance on the U.S. market. Timeline: 4-6 years.
Opportunities
- Expansion of PAD-IQ system applications to other vascular conditions.
- Increased adoption of PAD-IQ Studycast for telemedicine.
- Strategic partnerships with healthcare providers.
- Development of new wound care solutions.
Threats
- Competition from larger medical device companies.
- Regulatory changes impacting product development and market access.
- Economic downturn affecting healthcare spending.
- Technological advancements rendering existing products obsolete.
Competitive Advantages
- Specialized Product Portfolio: Vasamed's focus on hemodynamic health assessment provides a niche market position.
- Proprietary Technology: The SensiLase PAD-IQ system incorporates proprietary technology for accurate hemodynamic measurements.
- Established Customer Relationships: Vasamed has established relationships with clinicians and healthcare providers in the United States.
- PAD-IQ Studycast: Vasamed offers PAD-IQ Studycast for rapid transmission of diagnostic tests to vascular specialists.
About VSMD
Founded in 1988 and headquartered in Eden Prairie, Minnesota, Vasamed Incorporated operates within the healthcare sector, specifically focusing on medical instruments and supplies. The company designs, licenses, manufactures, and distributes products, software, and services aimed at assessing and managing hemodynamic health. Vasamed's flagship product is the SensiLase PAD-IQ system, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation using Doppler-obtained pressures. This system aids in the diagnosis and management of peripheral artery disease (PAD). In addition to PAD-IQ, Vasamed offers Wound Imaging & SmartDraw wound measurement systems, providing tools for clinicians to assess and track wound healing progress. The company also provides PAD-IQ Studycast, a service that facilitates rapid transmission of diagnostic tests to vascular specialists for interpretation and medically indicated therapeutic intervention. Vasamed serves clinicians and patients in the United States, offering a custom carrying case to secure and protect the PAD-IQ system, ensuring its portability and durability in clinical settings. Vasamed's solutions are designed to improve the accuracy and efficiency of hemodynamic assessments, supporting better patient outcomes in vascular health management.
What They Do
- Designs, licenses, manufactures, and distributes products for hemodynamic health assessment.
- Offers the SensiLase PAD-IQ system for skin perfusion pressure, pulse volume recording, and ankle brachial index calculation.
- Provides Wound Imaging & SmartDraw wound measurement systems.
- Offers PAD-IQ Studycast for rapid transmission of diagnostic tests to vascular specialists.
- Provides custom carrying cases to secure and protect the PAD-IQ system.
- Serves clinicians and patients in the United States.
Business Model
- Sales of SensiLase PAD-IQ system and related accessories.
- Licensing of software for hemodynamic assessment.
- Service revenue from PAD-IQ Studycast for remote diagnostics.
- Distribution of Wound Imaging & SmartDraw wound measurement systems.
Industry Context
Vasamed Incorporated operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. This industry is characterized by technological advancements, stringent regulatory requirements, and a competitive landscape featuring both large multinational corporations and smaller niche players. Market trends include a growing demand for non-invasive diagnostic tools, driven by an aging population and increasing prevalence of chronic diseases such as peripheral artery disease (PAD). Vasamed's focus on hemodynamic health assessment positions it within this growing market, but it faces competition from companies offering similar diagnostic solutions. The industry is also subject to regulatory oversight by agencies such as the FDA, which impacts product development and market access.
Key Customers
- Clinicians specializing in vascular health.
- Hospitals and clinics offering vascular diagnostic services.
- Vascular specialists interpreting diagnostic tests.
- Patients requiring hemodynamic health assessment and management.
VSMD Financials
VSMD Price Today & Live Chart
Vasamed, Inc. (VSMD) stock price: Price data unavailable
VSMD Latest News
No recent news available for VSMD.
VSMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VSMD.
Price Targets
Wall Street price target analysis for VSMD.
VSMD MoonshotScore
What does this score mean?
The MoonshotScore rates VSMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paulita LaPlante
CEO
Information about Paulita LaPlante's background is not available in the provided data. Without additional information, it is impossible to provide details about her career history, education, or previous roles. Further research would be required to complete this section.
Track Record: Information about Paulita LaPlante's track record is not available in the provided data. Without additional information, it is impossible to provide details about her key achievements, strategic decisions, or company milestones under her leadership. Further research would be required to complete this section.
VSMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Vasamed, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, and may not be required to adhere to strict regulatory guidelines. This tier is typically associated with higher risk and greater potential for volatility compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The unknown disclosure status increases information asymmetry and makes it difficult to assess the company's financial health.
- Low Liquidity: Trading on the OTC Other tier typically involves low trading volumes, leading to potential difficulties in buying or selling shares.
- Regulatory Scrutiny: OTC-listed companies may face increased regulatory scrutiny due to their lower listing standards.
- Volatility: OTC stocks are often more volatile than those listed on major exchanges.
- Going Concern Risk: Companies on the OTC Other tier may face a higher risk of financial distress or delisting.
- Verify the company's contact information and physical address.
- Investigate the background and experience of the company's management team.
- Attempt to obtain and review any available financial statements or disclosures.
- Assess the company's business model and competitive landscape.
- Determine if the company is subject to any legal or regulatory actions.
- Evaluate the company's capital structure and debt obligations.
- Consult with a qualified financial advisor before investing.
- Established Business Operations: Vasamed has been in operation since 1988, suggesting a degree of stability.
- Specialized Product Portfolio: The company focuses on a specific niche within the healthcare sector.
- Customer Base: Vasamed serves clinicians and patients in the United States.
- Proprietary Technology: The SensiLase PAD-IQ system incorporates proprietary technology.
VSMD Healthcare Stock FAQ
What does Vasamed, Inc. do?
Vasamed, Inc. specializes in the design, manufacture, and distribution of medical devices and software for hemodynamic health assessment. Its primary product, the SensiLase PAD-IQ system, is used by clinicians to diagnose and manage peripheral artery disease (PAD) through non-invasive measurements like skin perfusion pressure and ankle brachial index. The company also offers PAD-IQ Studycast, a service facilitating rapid transmission of diagnostic tests to vascular specialists. Vasamed serves clinicians and patients in the United States, providing tools to improve vascular health management.
What do analysts say about VSMD stock?
Due to the limited information available and the OTC Other listing, a comprehensive analyst consensus on VSMD stock is unavailable. Key valuation metrics such as P/E ratio (-0.00) and negative profit margin (-352.6%) suggest the company is not currently profitable. Growth considerations would focus on the company's ability to expand the applications of its PAD-IQ system, increase adoption of PAD-IQ Studycast, and manage its financial performance. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed stocks.
What are the main risks for VSMD?
The main risks for Vasamed, Inc. include its negative profit margin and gross margin, indicating financial instability and challenges in cost management. Competition from larger medical device companies poses a threat to its market share. As an OTC-listed company, VSMD faces risks associated with limited financial disclosure, low liquidity, and potential regulatory scrutiny. Additionally, changes in healthcare regulations and economic downturns could impact the company's business and financial performance. Investors should carefully consider these risks before investing in VSMD.
What are the key factors to evaluate for VSMD?
Vasamed, Inc. (VSMD) currently holds an AI score of 59/100, indicating moderate score. Key strength: Specialized product portfolio focused on hemodynamic health assessment. Primary risk to monitor: Negative profit margin of -352.6% indicates financial instability. This is not financial advice.
How frequently does VSMD data refresh on this page?
VSMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VSMD's recent stock price performance?
Recent price movement in Vasamed, Inc. (VSMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio focused on hemodynamic health assessment. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VSMD overvalued or undervalued right now?
Determining whether Vasamed, Inc. (VSMD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VSMD?
Before investing in Vasamed, Inc. (VSMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for Paulita LaPlante's background and track record.
- OTC analysis based on general characteristics of the OTC Other tier due to limited company-specific data.